I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diabetes prevalence in Morocco is estimated to be 6.4%.\[[@ref1]\] Fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy.\[[@ref2]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref3]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref4]\] This short communication presents the results for patients enrolled from Saiss, Morocco.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A~1~chieve study: Mapping the Ibn Battuta trail.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 145 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-naïve and insulin users is shown in the [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population. The majority of patients (38.6%) started on or were switched to insulin detemir. Other groups were biphasic insulin aspart (*n* = 47), insulin aspart (*n* = 1), basal insulin plus insulin aspart (*n* = 35) and other insulin combinations (*n* = 6).

###### 

Overall demographic data

![](IJEM-17-422-g001)

After 24 weeks of treatment, overall hypoglycaemic events or episodes reduced from 23.6 events/patient-year to 15.7 events/patient-year in insulin user group whereas hypoglycaemia increased from 2.3 events/patient-year to 3.1 events/patient-year in the insulin naïve group. However, this hypoglycaemia incidence in insulin naive group at 24 weeks was still lower than that observed in insulin users at baseline. SADRs including major hypoglycaemia did not occur in any of the study patients. Blood pressure decreased and lipid profile improved in the total cohort, but the findings were limited by number of observations. Quality of life improved after 24 weeks \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

###### 

Overall safety data
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###### 

Insulin dose

![](IJEM-17-422-g003)

All parameters of glycaemic control improved from baseline to study end in the total cohort \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data

![](IJEM-17-422-g004)

Biphasic insulin aspart ± OGLD {#sec2-1}
------------------------------

Of the total cohort, 47 patients started on biphasic insulin aspart ± OGLD, of which 33 (70.2%) were insulin naïve and 14 (29.8%) were insulin users. After 24 weeks of treatment, hypoglycaemic events reduced from 30.6 events/patient-year to 22.3 events/patient-year in insulin users while hypoglycaemia increased from 0.0 events/patient-year to 0.8 events/patient-year in insulin naïve group. Quality of life improved at 24 weeks \[Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug safety data

![](IJEM-17-422-g005)

###### 

Insulin dose

![](IJEM-17-422-g006)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups \[[Table 7](#T7){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug efficacy data
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Basal + insulin aspart ± OGLD {#sec2-2}
-----------------------------

Of the total cohort, 35 patients started on basal + insulin aspart ± OGLD, of which 10 (28.6%) were insulin naïve and 25 (71.4%) were insulin users. After 24 weeks of treatment, hypoglycaemic events reduced for both insulin naïve and insulin user groups (insulin naïve: from 13.0 events/patient-year to 8.7 events/patient-year, insulin user: from 25.0 events/patient-year to 17.1 events/patient-year). Quality of life improved after 24 weeks \[Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug safety data

![](IJEM-17-422-g008)

###### 

Insulin dose

![](IJEM-17-422-g009)

All parameters of glycaemic control improved from baseline to study end in those who started on or were basal + insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 10](#T10){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-422-g010)

Insulin detemir ± OGLD {#sec2-3}
----------------------

Of the total cohort, 56 patients started on insulin detemir ± OGLD, of which 44 (78.6%) were insulin naïve and 12 (21.4%) were insulin users. After 24 weeks of starting or switching to insulin detemir, hypoglycaemic events reduced from 14.1 events/patient-year to 6.5 events/patient-year in insulin users while hypoglycaemia increased from 1.8 events/patient-year to 4.0 events/patient-year in insulin naïve group. Quality of life improved after 24 weeks \[Tables [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug safety data

![](IJEM-17-422-g011)

###### 

Insulin dose

![](IJEM-17-422-g012)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for both insulin-naïve and insulin user groups \[[Table 13](#T13){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug efficacy data

![](IJEM-17-422-g013)

Insulin aspart ± OGLD {#sec2-4}
---------------------

Of the total cohort, only 1 patient started on or switched to insulin aspart ± OGLD and was insulin user.

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control following 24 weeks of treatment with any of the insulin analogues (biphasic insulin aspart; basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. Quality of life improved in the total cohort. SADRs including major hypoglycaemia did not occur in any of the study patients. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating Type 2 diabetes in Saiss, Morocco.
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